|
MG
MCID: MYS003
|
Myasthenia Gravis malady |
|
Sources: 30NIH Rare Diseases, 23MedlinePlus, 31NINDS, 17Genetics Home Reference, 44Wikipedia, 22MalaCards See all sources Export this MalaCard |
MedlinePlus: Myasthenia gravis is disease that causes weakness in the muscles under your control. it happens because of a problem in communication between your nerves and muscles. myasthenia gravis is an autoimmune disease. your body's own immune system makes antibodies that block or change some of the nerve signals to your muscles. this makes your muscles weaker.
common symptoms are trouble with eye and eyelid movement, facial expression and swallowing. but it can also affect other muscles. the weakness gets worse with activity, and better with rest..
there are medicines to help improve nerve-to-muscle messages and make muscles stronger. with treatment, the muscle weakness often gets much better. other drugs keep your body from making so many abnormal antibodies. there are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. sometimes surgery to take out the thymus gland helps.
for some people, myasthenia gravis can go into remission and they do not need medicines. the remission can be temporary or permanent.
if you have myasthenia gravis, it is important to follow your treatment plan. if you do, you can expect your life to be normal or close to it.
nih: national institute of neurological disorders and stroke23
MalaCards: Myasthenia Gravis, also known as myasthenia gravis without (acute) exacerbation, is related to thymoma and multiple sclerosis. An important gene associated with Myasthenia Gravis is AKAP12 (A kinase (PRKA) anchor protein 12), and among its related pathways are RAR-Gamma-RXR-Alpha Degradation and Cell adhesion molecules (CAMs). The drugs cyclophosphamide and cyclosporine and the compounds cyclophosphamide and polyethylene glycol have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, thymus and skeletal muscle, and related mouse phenotypes are endocrine/exocrine gland and respiratory system. NIH Rare Diseases: Myasthenia gravis is a chronic autoimmune neuromuscular disease. It is characterized by varying degrees of weakness of the skeletal muscles of the body. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expression, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improves after periods of rest.30 NINDS: Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. Symptoms vary in type and intensity. 31 Genetics Home Reference: Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.17 Wikipedia: Myasthenia gravis (from Greek μύς \"muscle\", ἀσθένεια \"weakness\", and Latin: gravis...44 more... |
|
Sources: 6Disease Ontology, 7diseasecard, 30NIH Rare Diseases, 17Genetics Home Reference, 31NINDS, 8DISEASES, 32Novoseek , 23MedlinePlus, 43UMLS, 19ICD9CM, 33OMIM, 40SNOMED-CT, 27NCIt, 24MeSH See all sources |
|
|
|
Sources: 4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 21LifeMap Discovery™, 43UMLS, 28NDF-RT See all sources |
Approved drugs:Search CenterWatch for myasthenia gravis Drug clinical trials:Search ClinicalTrials for myasthenia gravis Search NIH Clinical Center for myasthenia gravis Search CenterWatch for myasthenia gravis Inferred drug relations via UMLS/NDF-RT:43 28 cyclophosphamide, cyclosporine, pyridostigmine, pyridostigmine bromideCell-based therapeutics: The database of embryonic development, stem cell research and regenerative medicine Stem-Cell-Based therapeutic approaches for myasthenia gravis:
|
|
|
|
Sources: 22MalaCards See all sources |
MalaCards organs/tissues related to myasthenia gravis:22Bone marrow, Thymus, Skeletal muscle, Monocytes, T cells, B cells, Cardiac myocytes
|
|
Sources: 25MGI See all sources |
MGI Mouse Phenotypes related to myasthenia gravis:25 (show all 28)
|
|
Sources: 35PubMed See all sources |
Articles related to myasthenia gravis:(show top 50) (show all 357)
|
|
Sources: 1BioGPS See all sources |
  |
|
Sources: 36QIAGEN, 20KEGG, 37R&D Systems, 38Reactome, 10EMD Millipore, 41Thomson Reuters See all sources |
Pathways related to myasthenia gravis according to GeneDecks:(show top 50) (show all 127)
|
|
Sources: 32Novoseek , 34PharmGKB, 9DrugBank, 42Tocris Bioscience, 18HMDB See all sources |
Compounds related to myasthenia gravis according to GeneDecks:(show top 50) (show all 446)
|
|
Sources: 12Gene Ontology See all sources |
Cellular components related to myasthenia gravis according to GeneDecks:(show all 17)
Biological processes related to myasthenia gravis according to GeneDecks:(show top 50) (show all 75)
Molecular functions related to myasthenia gravis according to GeneDecks:(show all 14)
|